The use of deep brain stimulation at the VC/VS region is well tolerated for patients with Alzheimer disease.
In patients with mild Alzheimer's disease, solanezumab did not significantly reduce cognitive decline over time.
Obesity and associated comorbidities are seen to be potential contributers to Alzheimer disease pathophysiology.
In patients with mild cognitive impairment, CSF and MRI findings are highly predicitve of Alzheimer disease and dementia risk.
With special training and medication, Alzheimer's patients can relearn some basic skills.
Performance was consistently better in those who reported engaging in puzzles, and generally improved incrementally with the frequency of puzzle use.
Individuals with Alzheimer's disease are more likely to have low BMIs due to loss of appetite and weight loss in the early stages of the disease.
An Alzheimer's disease treatment study showed that after 18 weeks of treatment, only half of patients prescribed these drugs were continuing treatment.
Alzheimer's disease risk is not related to a past history of psychiatric disorders.
In 2016, an estimated 5.4 million US adults have Alzheimer disease.
Sundowning is a complex multifactorial condition that has eluded rigorous understanding of its pathophysiological causes.
Participants aged ≥65 years may have derived benefit from stimulation, while there was possible worsening in patients below age 65 years.
The effects of aggregate genetic AD risk are detectable before symptoms appear, even early in life.
Distinguishing between psychiatric disorders and AD is crucial because of the differing prognosis and management of the two.
If transmission of neurodegenerative diseases such as dementia of any type, AD, or PD does occur, it is rare.
Tetrahydrocannabinol (THC) is the main active chemical ingredient found in cannabis and is a potent cannabinoid receptor (CB)-1 agonist.
Although inconclusive, late-onset Alzheimer's Disease could be triggered by infectious pathogens.
Patients who were taking tacrolimus or cyclosporine after organ transplant had significantly lower rates of Alzheimer's compared to general public.
Individuals with type 'O' blood had more grey matter, thought to stave off cognitive decline, in their brains than other blood types.
The appearance of beta-amyloid plaque can rob memories in healthy brains before physical signs of neurocognitive degeneration appear in brain.
Patients with mild-to-moderate Alzheimer's and Parkinson's tended to experience more pain, yet those with other forms of cognitive impairment had less.
In early-onset and atypical forms of Alzheimer's, white matter degeneration could be an early biomarker prior to advancement of the disease.
A recent decision by a federal court has thwarted Actavis' alleged attempt to switch patients to Namenda XR prior to Namenda IR generics hitting market.
Seniors who consumed more Omega-3 fatty acids performed better on tests measuring cognitive flexibility.
Study involving more than 28,000 people in 40 countries finds those who scored highest on "healthy eating" index less likely to have memory decline.
Memory problems much more common in patients diagnosed with Alzheimer's at an older age.
People with frontotemporal dementia who had challenging jobs survived an average of 3.6 years longer than those with less challenging jobs.
Nonpharmacologic interventions should be used first before medication to promote sleep is considered.
However, treatment with a CPAP machine in patients with sleep apnea delayed onset of cognitive impairment.
People who drank a lot of milk had higher levels of the antioxidant glutathione, which is known to have protective properties for the brain.
Sign Up for Free e-newsletters
Psychiatry Advisor Articles
- Transference in the Age of #MeToo: What Counts as Harassment From a Patient?
- Should Physicians Treat Family and Friends? Three Experts Weigh In
- Predictors of Long-term Medication Adherence in Children With ADHD
- Influence of Psychostimulants on BMI and Height in Youth With ADHD
- Medication Adherence Predictors in Patients With Severe Psychiatric Disorders
- Court-Mandated Substance Abuse Treatment: Exploring the Ethics and Efficacy
- ADHD Treatments
- Esketamine Nasal Spray: A New Treatment Possibility for Treatment-Resistant Depression
- Pharmacogenetics in Psychiatry: Promising Developments and Potential Pitfalls
- Substance Abuse and Primary Psychosis: A Closer Look
- Functional Restoration for Chronic Pain and Depression in the Elderly: Pharmacotherapy and Beyond
- Efficacy of Long-Acting Injectable Antipsychotics vs Oral Antipsychotics
- Older Age Associated With Worse Major Depressive Disorder Outcomes
- Preoperative Psychiatric Diagnoses Not Associated With Bariatric Surgery Outcomes
- Medical Clearance of Psych Patients in the ED: Consensus Recommendations